204 related articles for article (PubMed ID: 18760123)
1. Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure.
Jiang W; O'Connor C; Silva SG; Kuchibhatla M; Cuffe MS; Callwood DD; Zakhary B; Henke E; Arias RM; Krishnan R;
Am Heart J; 2008 Sep; 156(3):437-44. PubMed ID: 18760123
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial.
O'Connor CM; Jiang W; Kuchibhatla M; Silva SG; Cuffe MS; Callwood DD; Zakhary B; Stough WG; Arias RM; Rivelli SK; Krishnan R;
J Am Coll Cardiol; 2010 Aug; 56(9):692-9. PubMed ID: 20723799
[TBL] [Abstract][Full Text] [Related]
3. Sertraline treatment of major depression in patients with acute MI or unstable angina.
Glassman AH; O'Connor CM; Califf RM; Swedberg K; Schwartz P; Bigger JT; Krishnan KR; van Zyl LT; Swenson JR; Finkel MS; Landau C; Shapiro PA; Pepine CJ; Mardekian J; Harrison WM; Barton D; Mclvor M;
JAMA; 2002 Aug; 288(6):701-9. PubMed ID: 12169073
[TBL] [Abstract][Full Text] [Related]
4. Trajectory classes of depression in a randomized depression trial of heart failure patients: a reanalysis of the SADHART-CHF trial.
Kuchibhatla MN; Fillenbaum GG
Am J Geriatr Pharmacother; 2011 Dec; 9(6):483-94. PubMed ID: 22035643
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study).
Jiang W; Krishnan R; Kuchibhatla M; Cuffe MS; Martsberger C; Arias RM; O'Connor CM;
Am J Cardiol; 2011 Feb; 107(4):545-51. PubMed ID: 21295172
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.
Hedayati SS; Gregg LP; Carmody T; Jain N; Toups M; Rush AJ; Toto RD; Trivedi MH
JAMA; 2017 Nov; 318(19):1876-1890. PubMed ID: 29101402
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
[TBL] [Abstract][Full Text] [Related]
8. Health status and depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial.
Xiong GL; Fiuzat M; Kuchibhatla M; Krishnan R; O'Connor CM; Jiang W;
Circ Heart Fail; 2012 Nov; 5(6):688-92. PubMed ID: 23065038
[TBL] [Abstract][Full Text] [Related]
9. Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants.
Glassman AH; Bigger JT; Gaffney M
Arch Gen Psychiatry; 2009 Sep; 66(9):1022-9. PubMed ID: 19736359
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF).
Angermann CE; Gelbrich G; Störk S; Fallgatter A; Deckert J; Faller H; Ertl G;
Eur J Heart Fail; 2007 Dec; 9(12):1212-22. PubMed ID: 18029292
[TBL] [Abstract][Full Text] [Related]
11. The Beyond Ageing Project Phase 2--a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial.
Cockayne NL; Duffy SL; Bonomally R; English A; Amminger PG; Mackinnon A; Christensen HM; Naismith SL; Hickie IB
Trials; 2015 Jun; 16():247. PubMed ID: 26037484
[TBL] [Abstract][Full Text] [Related]
12. Sertraline Versus Placebo in Patients with Major Depressive Disorder Undergoing Hemodialysis: A Randomized, Controlled Feasibility Trial.
Friedli K; Guirguis A; Almond M; Day C; Chilcot J; Da Silva-Gane M; Davenport A; Fineberg NA; Spencer B; Wellsted D; Farrington K
Clin J Am Soc Nephrol; 2017 Feb; 12(2):280-286. PubMed ID: 28126706
[TBL] [Abstract][Full Text] [Related]
13. Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit.
Glassman AH; Bigger JT; Gaffney M; Shapiro PA; Swenson JR
Arch Gen Psychiatry; 2006 Mar; 63(3):283-8. PubMed ID: 16520433
[TBL] [Abstract][Full Text] [Related]
14. The role of the selective serotonin re-uptake inhibitor sertraline in nondepressive patients with chronic ischemic heart failure: a preliminary study.
Leftheriotis D; Flevari P; Ikonomidis I; Douzenis A; Liapis C; Paraskevaidis I; Iliodromitis E; Lykouras L; Kremastinos DT
Pacing Clin Electrophysiol; 2010 Oct; 33(10):1217-23. PubMed ID: 20487349
[TBL] [Abstract][Full Text] [Related]
15. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
Angermann CE; Gelbrich G; Störk S; Gunold H; Edelmann F; Wachter R; Schunkert H; Graf T; Kindermann I; Haass M; Blankenberg S; Pankuweit S; Prettin C; Gottwik M; Böhm M; Faller H; Deckert J; Ertl G;
JAMA; 2016 Jun; 315(24):2683-93. PubMed ID: 27367876
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial.
Brady K; Pearlstein T; Asnis GM; Baker D; Rothbaum B; Sikes CR; Farfel GM
JAMA; 2000 Apr; 283(14):1837-44. PubMed ID: 10770145
[TBL] [Abstract][Full Text] [Related]
17. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial.
Keller MB; Kocsis JH; Thase ME; Gelenberg AJ; Rush AJ; Koran L; Schatzberg A; Russell J; Hirschfeld R; Klein D; McCullough JP; Fawcett JA; Kornstein S; LaVange L; Harrison W
JAMA; 1998 Nov; 280(19):1665-72. PubMed ID: 9831997
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
19. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
Banerjee S; Hellier J; Romeo R; Dewey M; Knapp M; Ballard C; Baldwin R; Bentham P; Fox C; Holmes C; Katona C; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; Orrell M; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Burns A
Health Technol Assess; 2013 Feb; 17(7):1-166. PubMed ID: 23438937
[TBL] [Abstract][Full Text] [Related]
20. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Banerjee S; Hellier J; Dewey M; Romeo R; Ballard C; Baldwin R; Bentham P; Fox C; Holmes C; Katona C; Knapp M; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; Orrell M; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Burns A
Lancet; 2011 Jul; 378(9789):403-11. PubMed ID: 21764118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
